Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: US-Based VC Firm Seeks New Therapeutics and Medical Device Investment Opportunities, Investing Up to $20M

8 Jul

A venture capital firm with offices in the US typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity. 
 
The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures. 
 
The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Subsidiary of China-Based Enterprise Partners With and Invests in Clinical-Stage Biotech and R&D Enabling Technologies, Investing Up to $100M

1 Jul

A U.S. subsidiary of a China-headquartered enterprise focused on advanced manufacturing and technical services, medical and healthcare, trade, and engineering services. The firm is seeking investment opportunities in life sciences and healthcare. The firm is open to various deal structures, including equity investments, M&A, and joint ventures. 
 

For equity investments, the firm’s sweet spots are Series A and Series B, although the firm is capable of making later-stage investments. Typical check sizes range from $10M to $100M. While primarily focused on opportunities in the U.S., the firm is also open to investments in North and South America. 
 
The firm is most interested in biotech therapeutics and pharmaceuticals and remains opportunistic regarding modalities and indications. The firm typically evaluates assets in Phase I or Phase II. Other areas of interest include hospital products, especially those leveraging AI, as well as surgical tools and R&D research technologies. 
 
The firm does not have specific requirements for a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Private Investment Firm Seeks Seed-Stage Investment Opportunities in Medical Devices and Digital Health Across the Globe

1 Jul

A privately funded investment firm based in Canada is focused on making direct investments in the following business sectors: medical technology, medical clinics, healthcare IT and healthcare real estate.  In medtech, the firm seeks to invest in seed stage companies.  The firm looks to partner and fund scientific founders to launch a new company and will primarily invest in the seed stage round. The firm typically allocates $100K-$200K, and will syndicate with other investors outside of their region to invest in larger rounds of $500K or more. The firm has physician, medical experience, particularly in the surgical field. The firm invests globally and is currently seeking new investment opportunities. 
 
In the life sciences, the firm is currently seeking to invest in medical devices and healthcare IT. The firm is opportunistic in terms of the class of device and indications, and has particular interest in surgical devices and tools. The firm is additionally interested in digital health, especially those with a software component. The firm prefers to invest in the pre-prototype stage and with particular preference to very early-stage preclinical technology. 
 
The firm is seeking startups with a maximum $5M pre-money valuation and will invest in pre-revenue companies. The firm is very hands-on after an investment, opening up and bringing their network to their portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Venture Arm of Foundation Invests in Seed to Series A Life Science Technologies that Address Brain Cancer and Adjacent CNS Diseases

1 Jul

A private family foundation dedicated to advancing brain tumor research employs a venture philanthropy investment model, which combines deep disease-focused expertise with funding for high-risk/high-reward opportunities. The foundation’s fund typically participates in seed to series A financing rounds with initial investment ranging from $250K to $1M and potential for follow-on investments. The fund is looking to make 3-5 investments per year, primarily within the US and Canada. As a subsidiary of the foundation, the fund will leverage the extensive network and expertise of the foundation and is active in supporting their portfolio companies. The fund does not typically lead rounds and more often co-invests. 
 
The fund focuses on primarily on brain tumor and will consider all technology types, including therapeutics, medical devices, and diagnostics. The fund will also consider adjacent spaces such as neuroscience, as long as there are potential implementations in brain cancer. The fund is also open to talking with companies that do not have a pipeline in brain cancer currently but have potential application in brain cancer in the future. The fund seeks to make investments that are impactful for the company, and typically prefers companies in pre-clinical or early clinical stages, especially for therapeutics. For diagnostics, the fund may consider assets that are in later stages of clinical development. 
 
An ideal founding team will have complementary skill sets, and expertise on the business or the fundraising front is a plus. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Pre-Seed and Seed Stage Focused Fund Seeks USA-Based Medical Device and Digital Health Technologies in Cardiology, Women’s Health, and More

1 Jul

A US-based venture fund invests only in seed and pre-seed rounds, and focuses solely on opportunities in healthcare IT, medtech and consumer health. The firm primarily invests in U.S. based companies but can invest in any geography. 
 
The firm invests in very early stage companies across the healthcare innovation ecosystem, including healthcare IT, medical devices, and consumer health. The firm is highly interested in preventative healthcare, future of work and healthcare IT applications. The firm is open to investing in any area of medicine, but has specific interest in opportunities in cardiology, pulmonary diseases, diabetes, and women’s health. 
 
The firm does not invest in companies that have already raised over $5 million in dilutive capital. The firm seeks to invest in high quality management teams, and prefers to work with experienced entrepreneurs that have a proven track record in their sector. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Europe-Based VC Firm Invests up to $25–30M Over the Company Lifecycle for Those Addressing Oncology or Genetic Diseases Across the Globe 

24 Jun

A global investor, headquartered in Western Europe with no geographical restrictions, and is actively seeking new investment opportunities. The firm is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic diseases. The firm makes selective investments in newly founded or early-stage companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. Typically, the firm invests in incorporated companies from seed stage onwards, and it can invest $25-30M over the lifetime of the companies. The firm’s current fund has a core strategy to invest in early stage companies, but the funds will also be used to invest in late stage financings, cross-over financings, IPO’s, and listed stock. These companies can either be portfolio companies or external companies. 
 
In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies and therapeutics targeting genetic diseases, and is open to all types of therapeutic modalities and all indications relevant to those spaces, including platform technologies. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Projects will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa). 
 
At its core, the firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of its portfolio companies. To this end, DROIA has several experts in oncology and genetic diseases, intellectual property, and drug development on the investment team which are available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Healthcare Focused VC Firm Invests in Promising Companies in North and South America, Across All Life Science Sectors

24 Jun

A healthcare technology-focused venture capital firm invests primarily in pre-Seed, Seed, Bridge, and Series A financing rounds and is currently investing from their second fund. Typical investment size ranges from $100-250k, with potential for follow on. The firm welcomes global opportunities, but will invest primarily in the “Americas” (North or South America). 
 
The firm is particularly interested in the areas of mental health, longevity, and chronic conditions, and technologies that can promote prevention, better access, and better quality of care. With their current fund, the firm seeks to invest into more biotech companies, and will consider all modalities. The firm will also continue to invest in medical devices, diagnostics, and digital health companies that address their key focus areas, with an open interest in various types of technologies within these main sectors. In terms of stage of development, the firm is open to pre-clinical, pre-revenue generating companies with demonstrated proof of concept. 
 
The firm does not have specific company or management team requirements. The firm can act as either a lead or co-investor, will typically seek board representation when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

← Older Entries
Newer Entries →